These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30825078)

  • 1. Inhibiting hepatic gluconeogenesis by chitosan lactate nanoparticles containing CRTC2 siRNA targeted by poly(ethylene glycol)-glycyrrhetinic acid.
    Rastegari A; Mottaghitalab F; Dinarvand R; Amini M; Arefian E; Gholami M; Atyabi F
    Drug Deliv Transl Res; 2019 Jun; 9(3):694-706. PubMed ID: 30825078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
    Li TS; Yawata T; Honke K
    Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular siRNA delivery dynamics of integrin-targeted, PEGylated chitosan-poly(ethylene imine) hybrid nanoparticles: A mechanistic insight.
    Ragelle H; Colombo S; Pourcelle V; Vanvarenberg K; Vandermeulen G; Bouzin C; Marchand-Brynaert J; Feron O; Foged C; Préat V
    J Control Release; 2015 Aug; 211():1-9. PubMed ID: 25989603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insight into glycyrrhetinic acid: the role of the hydroxyl group on liver targeting.
    Tian Q; Wang X; Wang W; Zhang C; Liu Y; Yuan Z
    Int J Pharm; 2010 Nov; 400(1-2):153-7. PubMed ID: 20813176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycyrrhetinic acid-modified graphene oxide mediated siRNA delivery for enhanced liver-cancer targeting therapy.
    Qu Y; Sun F; He F; Yu C; Lv J; Zhang Q; Liang D; Yu C; Wang J; Zhang X; Xu A; Wu J
    Eur J Pharm Sci; 2019 Nov; 139():105036. PubMed ID: 31446078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.
    Tian Q; Zhang CN; Wang XH; Wang W; Huang W; Cha RT; Wang CH; Yuan Z; Liu M; Wan HY; Tang H
    Biomaterials; 2010 Jun; 31(17):4748-56. PubMed ID: 20303163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes.
    Gu J; Al-Bayati K; Ho EA
    Drug Deliv Transl Res; 2017 Aug; 7(4):497-506. PubMed ID: 28315051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
    Zhang J; Zhang M; Ji J; Fang X; Pan X; Wang Y; Wu C; Chen M
    Pharm Res; 2015 Oct; 32(10):3376-90. PubMed ID: 26148773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. cAMP-responsive element-binding protein (CREB)-regulated transcription coactivator 2 (CRTC2) promotes glucagon clearance and hepatic amino acid catabolism to regulate glucose homeostasis.
    Erion DM; Kotas ME; McGlashon J; Yonemitsu S; Hsiao JJ; Nagai Y; Iwasaki T; Murray SF; Bhanot S; Cline GW; Samuel VT; Shulman GI; Gillum MP
    J Biol Chem; 2013 May; 288(22):16167-76. PubMed ID: 23595987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of siRNA targeting tumor metabolism using non-covalent PEGylated chitosan nanoparticles: Identification of an optimal combination of ligand structure, linker and grafting method.
    Corbet C; Ragelle H; Pourcelle V; Vanvarenberg K; Marchand-Brynaert J; Préat V; Feron O
    J Control Release; 2016 Feb; 223():53-63. PubMed ID: 26699426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRTC2 Is a Coactivator of GR and Couples GR and CREB in the Regulation of Hepatic Gluconeogenesis.
    Hill MJ; Suzuki S; Segars JH; Kino T
    Mol Endocrinol; 2016 Jan; 30(1):104-17. PubMed ID: 26652733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency.
    Ragelle H; Riva R; Vandermeulen G; Naeye B; Pourcelle V; Le Duff CS; D'Haese C; Nysten B; Braeckmans K; De Smedt SC; Jérôme C; Préat V
    J Control Release; 2014 Feb; 176():54-63. PubMed ID: 24389132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver-Targeted Co-delivery of Entecavir and Glycyrrhetinic Acid Based on Albumin Nanoparticle To Enhance the Accumulation of Entecavir.
    He S; Lin Q; Qu M; Wang L; Deng L; Xiao L; Zhang Z; Zhang L
    Mol Pharm; 2018 Sep; 15(9):3953-3961. PubMed ID: 30110554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of hepatic glucose metabolism via gluconeogenesis and glycogenolysis after oral administration of insulin nanoparticles.
    Woitiski CB; Neufeld RJ; Soares AF; Figueiredo IV; Veiga FJ; Carvalho RA
    Drug Dev Ind Pharm; 2012 Dec; 38(12):1441-50. PubMed ID: 22324290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
    Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
    Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of therapeutic efficacy of PLGA nanoformulation of siRNA targeting anti-apoptotic Bcl-2 through chitosan coating.
    Jagani HV; Josyula VR; Palanimuthu VR; Hariharapura RC; Gang SS
    Eur J Pharm Sci; 2013 Mar; 48(4-5):611-8. PubMed ID: 23291045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of PEG and water-soluble chitosan coating on moxifloxacin-loaded PLGA long-circulating nanoparticles.
    Mustafa S; Devi VK; Pai RS
    Drug Deliv Transl Res; 2017 Feb; 7(1):27-36. PubMed ID: 27576453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid stimulating hormone increases hepatic gluconeogenesis via CRTC2.
    Li Y; Wang L; Zhou L; Song Y; Ma S; Yu C; Zhao J; Xu C; Gao L
    Mol Cell Endocrinol; 2017 May; 446():70-80. PubMed ID: 28212844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance.
    Yhee JY; Song S; Lee SJ; Park SG; Kim KS; Kim MG; Son S; Koo H; Kwon IC; Jeong JH; Jeong SY; Kim SH; Kim K
    J Control Release; 2015 Jan; 198():1-9. PubMed ID: 25481438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy.
    Xie Y; Qiao H; Su Z; Chen M; Ping Q; Sun M
    Biomaterials; 2014 Sep; 35(27):7978-91. PubMed ID: 24939077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.